Telomir Pharmaceuticals is focused on advancing age reversal therapies through its innovative drug, Telomir-1, which uniquely modulates telomerase to repair and lengthen telomeres. This mechanism is crucial as telomeres protect DNA during cell division, and their degradation is linked to aging and age-related diseases. By promoting the elongation of telomeres, Telomir-1 aims to enhance the fidelity of DNA replication and potentially provide therapeutic interventions for age-related inflammatory conditions. The drug is currently under investigation for its ability to protect stem cells, thereby sustaining their self-renewal capabilities.

The efficacy of Telomir-1 is being evaluated through various preclinical studies, including trials on aged rats and laboratory beagle dogs. In these studies, Telomir-1 is assessed for its impact on osteoarthritis, with endpoints measuring joint pain and inflammation through advanced methodologies such as Dynamic Weight Bearing assessments and histopathological evaluations. Preliminary results indicate that Telomir-1 not only promotes telomere lengthening but also increases telomerase activity, suggesting its potential as a therapeutic agent in mitigating the effects of aging and improving joint health.

United States

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company focused on developing Telomir-1 as the first novel small molecule to lengthen telomeres, which are protective structures at the ends of chromosomes that play a key role in cellular aging and disease. The company is dedicated to the development and commercialization of therapeutic products for the treatment of age-related diseases and conditions.

Telomir Pharmaceuticals

Company Details